Clinical Trial Update: International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

View source ↗

Summary

An international expanded-access program for ramucirumab has been established to treat metastatic gastric cancer and metastatic adenocarcinoma of the gastroesop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Gastric Cancer

Drugs mentioned

• Cyramza (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Gastric Cancer, Metastatic Adenocarcinoma of the Gastroesophageal Junction | Status: APPROVED_FOR_MARKETING